... syndrome Pomalidomide Autologous stem cell transplantation Plasma cell neoplasm Bortezomib-refractory TEMPI syndrome is a subtype of plasma cell neoplasm that is characterized by 5 unique symptoms, including telangiectasias, elevated erythropoietin (EPO) and erythrocytosis, monoclonal...

... investigated in order to improve disease outcomes and spare patients the neurocognitive side effects. These include reduced-dose WBRT, non-myeloablative HD chemotherapy, or HD chemotherapy with autologous stem cell transplantation (HDC/ASCT). There are no randomized studies that compare all these consolidation...

... high-dose chemotherapy with autologous stem cell transplantation, whereas others who have multiple comorbidities with reduced renal and bone marrow function can tolerate only intermediate doses of methotrexate. The latter may benefit from maintenance treatment. The “elderly” are also susceptible...

.... Multiple myeloma Autologous stem cell transplantation Induction Cyclophosphamide Bortezomib Dexamethasone Weekly cyclophosphamide-bortezomib-dexamethasone Multiple myeloma (MM) is an incurable plasma cell neoplasm diagnosed in 5–6 per 100,000 individuals annually in the Japanese population...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Multiple myeloma Autologous stem cell transplantation Immunophenotype...

... associated with the use of novel agents followed by autologous stem cell transplantation (ASCT) in IgD MM patients. We evaluated the clinical outcomes of induction treatment with novel agents followed by ASCT. Methods: This was a single-center, retrospective study of 22 IgD MM patients who underwent ASCT...

...; Wolfgang E. Berdel Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single ( n = 286) or tandem ( n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally...

.... Allogeneic stem cell transplantation Autologous stem cell transplantation Transformed low-grade lymphoid malignancy Low-grade lymphomas represent 40% of non-Hodgkin lymphomas (NHLs) [ 1 ]. Although low-grade NHLs are known to be indolent and respond well to chemotherapy or immunotherapy, they have...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2014 Acute myeloid leukemia t(8;21) Reduced intensity conditioning Autologous stem cell transplantation Translocation (8;21) (q22;q22) [t(8;21)] along...

...-hematopoietic SCT in the treatment of PTCL, we conducted a systematic literature review and meta-analysis to evaluate the role of allo-SCT for PTCL. Peripheral T-cell lymphoma Allogeneic stem cell transplantation Autologous stem cell transplantation Lymphomas Meta-analysis © 2014 S. Karger AG...

..., instructions or products referred to in the content or advertisements. Myeloma Autologous stem cell transplantation Induction therapy Autologous stem cell transplantation (ASCT) has been an integral part of the treatment of newly diagnosed myeloma patients since it was found to improve...

... and the European Myeloma Network Novel agents such as thalidomide, lenalidomide and bortezomib have dramatically changed the treatment paradigm of multiple myeloma (MM). However, it is not clear whether these agents improve the prognosis of elderly patients who have undergone autologous stem cell transplantation...

...J. Yin; J. Wei; J.H. Xu; Y. Xiao; Y.C. Zhang Objective: In view of the poor prognosis of most peripheral T cell lymphoma (PTCL) subtypes treated with conventional chemotherapy such as CHOP/CHOP-like regimens, high-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) seems...

... associated with aplastic anemia or other bone marrow (BM) failure syndromes. We report a previously undescribed case of PNH occurring after autologous stem cell transplantation (ASCT) in a patient affected by relapsing non-Hodgkin’s lymphoma. The intensive chemotherapy and the ASCT resulted in a contraction...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Acute myeloid leukemia Autologous stem cell transplantation Meta-analysis...

... autologous stem cell transplantation for severe autoimmune diseases. High frequencies of posttransplant recurring naive Th cells coexpressed CD31 and stable long-term reconstitution with elevated absolute counts of CD31+ thymus-naive Th cells that were enriched with T cell receptor excision circles...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Autologous stem cell transplantation High-dose idarubicin Multiple myeloma...

... supported by autologous stem cell transplantation (autoSCT). Taken together, immunotherapy following autoSCT may provide an ideal combination for improving the cure rate of otherwise incurable cancers, especially if tumor cells may respond to cytokine-mediated immunotherapy or cell-mediated cytokine...

... have led to the increasing use of HDT followed by ASCT in patients with relapsed or refractory lymphoma. A large number of phase II trials of autologous stem cell transplantation in patients with relapsed/refractory DLBCL have been published [ 14,15,16,17,18,19,20,21,22,23 ] with a median 3-year...

... in patients undergoing autologous stem cell transplantation for hematological malignancies or solid tumors. 2 11 2005 © 2005 S. Karger AG, Basel 2005 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages...